Key risks
Valuation at PE 90.94 embeds significant growth expectations; any shortfall on growth or profitability would trigger sharp re-rating
Operating margin compressed from 23.43% (Q3 FY26) to 20.25% (Q4 FY26) sequentially — verify if this reflects temporary cost pressure or structural headwinds
ROE of 9.06% is modest relative to typical cost of capital; verify if management plans to improve capital efficiency or returns will remain constrained
Healthcare services face regulatory risk from government price controls and reimbursement policy shifts — verify Nephrocare's exposure to government schemes and pricing flexibility
Generated analysis · source review pending